Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 7:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 515 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Target Lesion Clear all
Completed Early Phase 1 Interventional

Study of Neuroimaging Biomarkers of Social Cognition Deficits in Adolescents (Age 13-17) With Autism Spectrum Disorder and Effects of Gabapentin

NCT03589898
View directory record Official record
Conditions
Autism Spectrum Disorder
Interventions
Gabapentin
Drug
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
13 Years to 17 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 2, 2022 · Synced Oct 23, 2026, 7:02 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

DUVAX: A Phase 1 Alzheimer's Vaccine Study Targeting Amyloid-Beta and Tau

NCT07142278
View directory record Official record
Conditions
Alzheimer Disease, Alzheimer Disease (AD), Preclinical Alzheimer's Disease
Interventions
DUVAX 200 µg, DUVAX 400 µg, Placebo (Adjuvant only)
Biological
Lead sponsor
Nuravax, Inc.
Industry
Eligibility
40 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Miami Lakes, Florida
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 23, 2026, 7:02 AM EDT
Completed Phase 2 Interventional Results available

Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1)

NCT05103358
View directory record Official record
Conditions
Tumor, Tumor, Solid, Metastasis, Metastatic Cancer, Cancer, Cancer Metastatic, Tumors, Neoplasms, Neoplasm Metastasis, Solid Tumor, Advanced Solid Tumor, Advanced Cancer, Malignant Solid Tumor, Malignant Solid Neoplasm, Malignant Neoplasm, Malignant Tumor, TSC, TSC1, TSC2, Metastatic Solid Tumor, Metastatic Neoplasm
Interventions
nab-sirolimus
Drug
Lead sponsor
Aadi Bioscience, Inc.
Industry
Eligibility
12 Years and older
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
159
States / cities
Birmingham, Alabama • Mobile, Alabama • Goodyear, Arizona + 137 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 23, 2026, 7:02 AM EDT
Completed Phase 3 Interventional Results available

Patient-Reported and Radiographic Outcomes in Evaluating Lorecivivint (SM04690) for the Treatment of Knee Osteoarthritis

NCT03928184
View directory record Official record
Conditions
Knee Osteoarthritis
Interventions
Lorecivivint, Placebo
Drug
Lead sponsor
Biosplice Therapeutics, Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
501 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
99
States / cities
Birmingham, Alabama • Peoria, Arizona • Phoenix, Arizona + 85 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2026 · Synced Oct 23, 2026, 7:02 AM EDT
Terminated Phase 2 Interventional Results available

A Study to Evaluate Efficacy and Safety of GSK3858279 in Diabetic Peripheral Neuropathic Pain

NCT05838755
View directory record Official record
Conditions
Pain
Interventions
GSK3858279, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
19
States / cities
Anniston, Alabama • Surprise, Arizona • Cerritos, California + 15 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2025 · Synced Oct 23, 2026, 7:02 AM EDT
Completed Phase 3 Interventional

Strategies to Maintain Cardiac Risk Control After Discharge From Cardiovascular Risk Reduction Clinic

NCT00358033
View directory record Official record
Conditions
Diabetes, Dyslipidemia, Hypertension, Coronary Atherosclerosis
Interventions
Counseling, Interactive Education, Group Support, Pharmacologic case management
Behavioral · Procedure
Lead sponsor
Providence VA Medical Center
Federal
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Apr 16, 2014 · Synced Oct 23, 2026, 7:02 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Response-Adapted Therapy With Copanlisib and Rituximab in Untreated Follicular Lymphoma

NCT03789240
View directory record Official record
Conditions
Follicular Lymphoma, Non-Hodgkin's Lymphoma, NHL
Interventions
Rituximab, Copanlisib, Bone Marrow Aspiration/Biopsy, CT Scans, 18F-FDG-PET/CT Scan15, Electrocardigram
Biological · Drug · Procedure + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Oct 23, 2026, 7:02 AM EDT
Completed Phase 2 Interventional Results available

Tariquidar and Docetaxel to Treat Patients With Lung, Ovarian, Renal and Cervical Cancer

NCT00069160
View directory record Official record
Conditions
Lung Neoplasms, Ovarian Neoplasms, Cervix Neoplasms, Renal Neoplasms
Interventions
docetaxel, tariquidar, 99mTc-sestamibi imaging
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 12, 2012 · Synced Oct 23, 2026, 7:02 AM EDT
Active, not recruiting Not applicable Interventional

Preductal Oxygen Saturation Target in Term and Late Preterm Neonates With Hypoxemic Respiratory Failure or Pulmonary Hypertension

NCT04938167
View directory record Official record
Conditions
Persistent Pulmonary Hypertension of the Newborn, Hypoxemic Respiratory Failure
Interventions
95% - 99% SpO2 target
Other
Lead sponsor
University of California, Davis
Other
Eligibility
0 Days to 28 Days
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Oct 23, 2026, 7:02 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Assessment of [18F]-Fluorocellobiose ([18F]FCB) Pharmacokinetics in Healthy Volunteers and Subjects With Invasive Mold Infections

NCT07704333
View directory record Official record
Conditions
Aspergillos, Mucormye, Dimorphic, Other Molds, Non-Aspergillos, Non-Mucormycosis
Interventions
[18F]-Fluorocellobiose ([18F]FCB)
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years to 100 Years
Enrollment
98 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 23, 2026, 7:02 AM EDT
Completed Phase 4 Interventional Results available

Efficacy and Safety of Basal-bolus Therapy, Comparing Stepwise Addition of Insulin Aspart Versus Complete Basal-bolus Regimen

NCT01165684
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
insulin aspart, insulin detemir
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
401 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
33
States / cities
Birmingham, Alabama • Mesa, Arizona • Scottsdale, Arizona + 28 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2017 · Synced Oct 23, 2026, 7:02 AM EDT
Terminated Phase 2 Interventional Results available

Spesolimab in Pyoderma Gangrenosum

NCT06092216
View directory record Official record
Conditions
Pyoderma Gangrenosum
Interventions
Spesolimab
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Oct 23, 2026, 7:02 AM EDT
Not yet recruiting No phase listed Observational

SnapChole: An International, Time-Bound Prospective Platform Study of Management Strategies and Outcomes in Acute Calculous Cholecystitis

NCT07568080
View directory record Official record
Conditions
Cholecystitis, Acute
Interventions
Not listed
Lead sponsor
European Society for Trauma and Emergency Surgery
Other
Eligibility
18 Years and older
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 23, 2026, 7:02 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Positron Emission Tomography (PET) Trial to Evaluate Target Occupancy of CVL-354 at Kappa and Mu Opioid Receptors in Brain Following Oral Dosing

NCT05547542
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
CVL-354, [11C]-LY2795050, [11C]-carfentanil
Drug
Lead sponsor
Cerevel Therapeutics, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
2
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 14, 2025 · Synced Oct 23, 2026, 7:02 AM EDT
Completed Phase 1 Interventional

DNX-2401 With Interferon Gamma (IFN-γ) for Recurrent Glioblastoma or Gliosarcoma Brain Tumors

NCT02197169
View directory record Official record
Conditions
Glioblastoma or Gliosarcoma
Interventions
Single intratumoral injection of DNX-2401, Interferon-gamma
Drug
Lead sponsor
DNAtrix, Inc.
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
4
States / cities
Tampa, Florida • Columbus, Ohio • Dallas, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2018 · Synced Oct 23, 2026, 7:02 AM EDT
Terminated Phase 1 Interventional

RBX7455 Before Surgery for the Treatment of Operable Breast Cancer

NCT04139993
View directory record Official record
Conditions
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Breast Adenocarcinoma, Invasive Breast Carcinoma, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Triple-Negative Breast Carcinoma
Interventions
Microbiota-based Formulation RBX7455
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Oct 4, 2023 · Synced Oct 23, 2026, 7:02 AM EDT
Recruiting Phase 1 Interventional

Autologous B7-H3 Chimeric Antigen Receptor T Cells in Relapsed/Refractory Solid Tumors

NCT06500819
View directory record Official record
Conditions
Neuroblastoma, Sarcoma, Osteosarcoma
Interventions
B7-H3CART Dose (Intravenous)
Drug
Lead sponsor
Stanford University
Other
Eligibility
2 Years to 30 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Oct 23, 2026, 7:02 AM EDT
Completed Phase 1 Interventional

Clinical Study to Evaluate Safety and Maximum Tolerated Dose of BAY1000394 Given in a 4 Week on / 2 Week Off Schedule in Subjects With Advanced Malignancies

NCT01335256
View directory record Official record
Conditions
Neoplasms
Interventions
BAY1000394
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
3
States / cities
Scottsdale, Arizona • St Louis, Missouri • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 3, 2013 · Synced Oct 23, 2026, 7:02 AM EDT
Recruiting Phase 1 Interventional

Autologous Gamma Delta T Cells to Target Prostate Stem Cell Antigen in mCRPC

NCT06193486
View directory record Official record
Conditions
Metastatic Castration-resistant Prostate Cancer
Interventions
MSGV1-PSCA-8T28Z, Fludarabine, Cyclophosphamide
Biological · Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2033
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Oct 23, 2026, 7:02 AM EDT
Completed Phase 1 Interventional

MLN9708 and Vorinostat in Patients With Advanced p53 Mutant Malignancies

NCT02042989
View directory record Official record
Conditions
Advanced Cancers
Interventions
MLN9708, Vorinostat
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 11, 2022 · Synced Oct 23, 2026, 7:02 AM EDT
Terminated No phase listed Observational

Evaluation of Vancomycin Treatment of Infections Due to Staphylococcus Aureus

NCT00862862
View directory record Official record
Conditions
Staphylococcus Aureus
Interventions
Not listed
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Aug 23, 2023 · Synced Oct 23, 2026, 7:02 AM EDT
Completed No phase listed Observational Results available

The Patient-Reported Outcomes Project of HCV-TARGET

NCT02601820
View directory record Official record
Conditions
Hepatitis C, Chronic, Liver Diseases
Interventions
Not listed
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
21 Years and older
Enrollment
1,601 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
11
States / cities
Davis, California • New Haven, Connecticut • Gainesville, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2019 · Synced Oct 23, 2026, 7:02 AM EDT
Completed Not applicable Interventional Results available

Optimal Planning Target Volume With Stereotactic Radiosurgery

NCT01017497
View directory record Official record
Conditions
Brain Neoplasms, Brain Cancer
Interventions
Stereotactic Radiosurgery
Radiation
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 13, 2015 · Synced Oct 23, 2026, 7:02 AM EDT
Completed Phase 2 Interventional

Add Glucokinase Activator to Target A1c

NCT02405260
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
TTP399 400 mg, TTP399 800 mg, Sitagliptin 100 mg, Placebo
Drug
Lead sponsor
vTv Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
20
States / cities
Mesa, Arizona • Tuscon, Arizona • Canoga Park, California + 16 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2017 · Synced Oct 23, 2026, 7:02 AM EDT